Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.
In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four oral contraceptives (OCs) on various hormone parameters and serum-binding globulins was investigated. Four groups with 25 volunteers each (18-35 years of age) were treated for six cycles with monophasic combinations containing 21 tablets with either 30 microg ethinylestradiol (EE) + 2 mg dienogest (DNG) (30EE/DNG), 20 microg EE + 2 mg DNG (20EE/DNG), 10 microg EE + 2 mg estradiol valerate (EV) + 2 mg DNG (EE/EV/DNG) or 20 microg EE + 100 microg levonorgestrel (LNG) (EE/LNG). The study was completed by 91 subjects. Blood samples were taken after at least 12 h of fasting on Day 21-26 of the preceding control cycle and on Day 18-21 of the first, third and sixth treatment cycle. The serum concentrations of free testosterone were significantly decreased by about 40-60% in all four groups, while those of dehydroepiandrosterone sulfate (DHEAS) showed a time-dependent decrease during treatment. Except for EE/EV/DNG, which increased prolactin significantly during the third and sixth cycles, no change was observed with the EE-containing preparations. There was a significant increase in the levels of serum-binding globulins during treatment, which differed according to the composition of the OCs used. The rise in sex hormone-binding globulin (SHBG) was highest during intake of 30EE/DNG (+320%) and lowest with EE/LNG (+80%), while the effect of 20EE/DNG and EE/EV/DNG was similar (+270%). The thyroxine-binding globulin (TBG) levels increased significantly, by 50-60%, during treatment with the DNG-containing formulations, while the effect of EE/LNG was less significant (+30%). The rise in corticosteroid-binding globulin (CBG), which occurred in all groups, was most pronounced in women treated with 30EE/DNG (+90%) and least with EE/EV/DNG (+55%), indicating a strong influence of EE and no effect of the progestogen component. In all treatment groups, the frequency of intracyclic bleeding rose in the first treatment cycle and decreased thereafter. Cycle control was significantly better with 30EE/DNG or EE/LNG than with 20EE/DNG or EE/EV/DNG. There was no significant change in blood pressure, body mass index or pulse rate throughout the study. In conclusion, the DNG-containing OCs caused a higher rise in SHBG and TBG levels than the LNG-containing preparation. The effects on CBG suggest a lesser hepatic effect of 2 mg EV as compared to 20 or 30 microg EE. In contrast to EE, the use of estradiol in OCs appeared to increase prolactin release, while the cycle control was better with the OC containing 30 microg EE.
Wiegratz
I
I
Department of Obstetrics and Gynecology, J. W. Geothe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.
Kutschera
E
E
Lee
J H
JH
Moore
C
C
Mellinger
U
U
Winkler
U H
UH
Kuhl
H
H
D000293:Adolescent; D000328:Adult; D003276:Contraceptives, Oral / Q000494:pharmacology*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012016:Reference Values; D012738:Sex Hormone-Binding Globulin / Q000187:drug effects*; D013739:Testosterone / Q000097:blood; D013975:Thyroxine-Binding Proteins / Q000187:drug effects*; D016896:Treatment Outcome
D003276:Contraceptives, Oral; D012739:Gonadal Steroid Hormones; D012738:Sex Hormone-Binding Globulin; D013975:Thyroxine-Binding Proteins; D013739:Testosterone; D004997:Ethinyl Estradiol; C023635:dienogest; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D016912:Levonorgestrel; D009277:Nandrolone